Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 2
2020 1
2021 2
2022 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Unconventional non-amino acidic PET radiotracers for molecular imaging in gliomas.
Laudicella R, Quartuccio N, Argiroffi G, Alongi P, Baratto L, Califaretti E, Frantellizzi V, De Vincentis G, Del Sole A, Evangelista L, Baldari S, Bisdas S, Ceci F, Iagaru A; Young Italian Association of Nuclear Medicine (AIMN) group. Laudicella R, et al. Eur J Nucl Med Mol Imaging. 2021 Nov;48(12):3925-3939. doi: 10.1007/s00259-021-05352-w. Epub 2021 Apr 13. Eur J Nucl Med Mol Imaging. 2021. PMID: 33851243 Review.
Correction to: Unconventional non-amino acidic PET radiotracers for molecular imaging in gliomas.
Laudicella R, Quartuccio N, Argiroffi G, Alongi P, Baratto L, Califaretti E, Frantellizzi V, De Vincentis G, Del Sole A, Evangelista L, Baldari S, Bisdas S, Ceci F, Iagaru A; Young Italian Association of Nuclear Medicine (AIMN) group. Laudicella R, et al. Eur J Nucl Med Mol Imaging. 2022 May;49(6):2104. doi: 10.1007/s00259-022-05760-6. Eur J Nucl Med Mol Imaging. 2022. PMID: 35301587 No abstract available.
Low RNA disruption during neoadjuvant chemotherapy predicts pathologic complete response absence in patients with breast cancer.
Cazzaniga ME, Ademuyiwa F, Petit T, Tio J, Generali D, Ciruelos EM, Califaretti N, Poirier B, Ardizzoia A, Hoenig A, Lex B, Mouret-Reynier MA, Giesecke D, Isambert N, Masetti R, Pitre L, Wrobel D, Augereau P, Milani M, Rask S, Solbach C, Pritzker L, Noubir S, Parissenti A, Trudeau ME. Cazzaniga ME, et al. JNCI Cancer Spectr. 2024 Jan 4;8(1):pkad107. doi: 10.1093/jncics/pkad107. JNCI Cancer Spectr. 2024. PMID: 38113421 Free PMC article.
Remote, proactive, telephone based management of toxicity in outpatients during adjuvant or neoadjuvant chemotherapy for early stage breast cancer: pragmatic, cluster randomised trial.
Krzyzanowska MK, Julian JA, Gu CS, Powis M, Li Q, Enright K, Howell D, Earle CC, Gandhi S, Rask S, Brezden-Masley C, Dent S, Hajra L, Freeman O, Spadafora S, Hamm C, Califaretti N, Trudeau M, Levine MN, Amir E, Bordeleau L, Chiarotto JA, Elser C, Husain J, Laferriere N, Rahim Y, Robinson AG, Vandenberg T, Grunfeld E. Krzyzanowska MK, et al. BMJ. 2021 Dec 8;375:e066588. doi: 10.1136/bmj-2021-066588. BMJ. 2021. PMID: 34880055 Free PMC article. Clinical Trial.
RESULTS: Baseline characteristics of participants were similar in the intervention (n=944) and control arms (n=1214); 22% were older than 65 years. ...
RESULTS: Baseline characteristics of participants were similar in the intervention (n=944) and control arms (n=1214); 22% were …
A multicentre, randomised trial comparing schedules of G-CSF (filgrastim) administration for primary prophylaxis of chemotherapy-induced febrile neutropenia in early stage breast cancer.
Clemons M, Fergusson D, Simos D, Mates M, Robinson A, Califaretti N, Zibdawi L, Bahl M, Raphael J, Ibrahim MFK, Fernandes R, Pitre L, Aseyev O, Stober C, Vandermeer L, Saunders D, Hutton B, Mallick R, Pond GR, Awan A, Hilton J. Clemons M, et al. Ann Oncol. 2020 Jul;31(7):951-957. doi: 10.1016/j.annonc.2020.04.005. Epub 2020 Apr 20. Ann Oncol. 2020. PMID: 32325257 Free article. Clinical Trial.
A protocol amendment in November 2017 allowed subsequent patients (N = 324) to be randomised to either 5 or 7/10 days. The primary outcome was a composite of either FN or treatment-related hospitalisations. ...Analyses were carried out by per protocol (primary) and intenti …
A protocol amendment in November 2017 allowed subsequent patients (N = 324) to be randomised to either 5 or 7/10 days. The primary ou …
A comprehensive metabolic evaluation reveals impaired glucose metabolism and dyslipidemia in breast cancer patients early in the disease trajectory.
Bell KE, Di Sebastiano KM, Vance V, Hanning R, Mitchell A, Quadrilatero J, Russell C, Dubin JA, Bahl M, Califaretti N, Campbell C, Mourtzakis M. Bell KE, et al. Clin Nutr. 2014 Jun;33(3):550-7. doi: 10.1016/j.clnu.2013.08.001. Epub 2013 Aug 15. Clin Nutr. 2014. PMID: 24011971
We aimed to characterize glucose metabolism in breast cancer patients near the initiation of chemotherapy. METHODS: Stage I-II breast cancer patients (n = 8) were evaluated near the initiation of chemotherapy and compared with a group of age- and body mass index-matched, a …
We aimed to characterize glucose metabolism in breast cancer patients near the initiation of chemotherapy. METHODS: Stage I-II breast cancer …
Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study.
Clemons MJ, Cochrane B, Pond GR, Califaretti N, Chia SK, Dent RA, Song X, Robidoux A, Parpia S, Warr D, Rayson D, Pritchard KI, Levine MN. Clemons MJ, et al. Breast Cancer Res Treat. 2014 Jul;146(1):153-62. doi: 10.1007/s10549-014-3015-6. Epub 2014 Jun 13. Breast Cancer Res Treat. 2014. PMID: 24924416 Clinical Trial.
Biomarkers of bone turnover, including urine N-telopeptide (uNTx), have been used as surrogate measures of response to bone-targeted therapies. ...
Biomarkers of bone turnover, including urine N-telopeptide (uNTx), have been used as surrogate measures of response to bone-targeted …